CTT Pharma Signs LOI with European Company

Rhea-AI Summary

CTT Pharmaceutical (OTCQB:CTTH) signed a letter of intent with another company to conduct clinical trials and testing for potential nicotine products based on CTT's patented technology. A resulting partnership could enable CTT to independently enter the U.S. nicotine market. Further details will be shared with shareholders.

News Market Reaction – CTTH

+11.11%

+11.11% Session close to close

In the Jun 17 session, CTTH gained 11.11%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TAMPA, FL / ACCESS Newswire / June 17, 2026 / CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has signed an LOI with a company in the United States to conduct clinical trials and testing for several potential nicotine products for CTT Pharma. A partnership with this company would allow CTT the ability to independently go to market in the United States utilizing our patented technology. CTT Pharma will notify shareholders as more information becomes available.

About CTT Pharmaceutical Holdings, Inc.

CTT Pharmaceutical Holdings, Inc. is a pharmaceutical technology company specializing in the development and commercialization of thin film oral drug delivery systems designed to provide rapid onset, enhanced patient convenience, and efficient absorption. The Company's patented micelle based thin film platform is intended to offer a novel alternative to traditional dosage forms across pharmaceutical, therapeutic, and nutraceutical markets. CTT is focused on integrating scientific validation, scalable manufacturing, and regulatory preparedness to support long-term growth and product innovation.

Forward-Looking Statements

Forward-looking statements include statements regarding the Company's plans, objectives, expectations, and intentions, including potential future business operations. Words such as anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, should, will, would and similar expressions identify forward-looking statements. These statements are based on management's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Important factors that could cause such differences include, but are not limited to: the timing and outcome of a potential partnership. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

CTT Pharmaceutical Holdings, Inc.
813-606-0060

SOURCE: CTT Pharmaceutical Holdings, Inc.

View the original press release on ACCESS Newswire

FAQ

What did CTT Pharma (OTCQB:CTTH) announce on June 17, 2026?

CTT Pharma announced a letter of intent with another company to run clinical trials and testing for several potential nicotine products. According to CTT Pharma, this arrangement focuses on using its patented technology and may support future commercialization plans.

How could the new LOI impact CTT Pharma's nicotine product strategy (CTTH)?

The LOI could support clinical trials and testing for potential nicotine products built on CTT Pharma’s patented technology. According to CTT Pharma, a finalized partnership may help the company independently bring nicotine products to the U.S. market in the future.

Does the CTT Pharma LOI mean a finalized partnership for CTTH shareholders?

No, the LOI does not represent a finalized partnership; it outlines intent to collaborate. According to CTT Pharma, the company will update shareholders as discussions progress and more information about any definitive agreement or project scope becomes available.

What type of products are targeted in CTT Pharma's new LOI for CTTH?

The LOI targets clinical trials and testing for several potential nicotine products that use CTT Pharma’s patented technology. According to CTT Pharma, these products are still in the exploratory stage and will require further development and regulatory review.

How might CTT Pharma's LOI affect its ability to enter the U.S. market (CTTH)?

If a partnership is finalized, CTT Pharma believes it could independently go to market in the United States with nicotine products. According to CTT Pharma, this potential depends on successful trials, testing outcomes, and future regulatory and commercial steps.

What updates can CTTH investors expect after CTT Pharma's LOI announcement?

CTT Pharma has said it will notify shareholders as more information becomes available about the LOI and any resulting partnership. According to CTT Pharma, future updates should clarify development plans, clinical timelines, and potential commercialization paths for nicotine products.